Beclomethasone Dipropionate

證據等級: L5

預測適應症: 1 個

Beclomethasone Dipropionate: From Asthma / Allergic Rhinitis to Atopic Eczema

One-Sentence Summary

Beclomethasone dipropionate (BDP) is a synthetic glucocorticoid corticosteroid with established use in asthma and allergic rhinitis via inhaled and intranasal routes. The TxGNN model predicts it may be effective for atopic eczema, with a prediction score of 99.41%. Current evidence includes no registered clinical trials but 18 publications — among them 1 randomized controlled trial from 1984 demonstrating significant benefit in severe pediatric atopic eczema.

Quick Overview

Item	Content
Original Indication	Asthma, Allergic Rhinitis (glucocorticoid class; no regulatory license data available)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.41%
Evidence Level	L2 (1 RCT identified in literature)
Market Status	Not Marketed (0 approved licenses on record)
Number of Approved Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Beclomethasone dipropionate is a synthetic glucocorticoid that acts as a glucocorticoid receptor (GR) agonist. By suppressing the transcription factors NF-κB and AP-1, it inhibits downstream Th2 cytokines — notably IL-4, IL-13, and IL-31 — while reducing mast cell and eosinophil infiltration into target tissues. This mechanism underlies BDP’s well-established efficacy in asthma and allergic rhinitis.

Atopic eczema is fundamentally a Th2-mediated inflammatory disease of the skin barrier. The pathological drivers BDP targets — Th2 cytokine excess, eosinophil recruitment, and mast cell activation — are precisely the same mechanisms central to atopic eczema flares. This is not an indirect connection: the mechanistic overlap is direct and biologically well-grounded. When delivered via oral or intranasal routes, BDP can achieve systemic immunomodulatory effects that extend beyond the reach of topical-only application, which is the biological basis for considering BDP as a repurposing candidate in this indication.

The TxGNN knowledge graph assigns a very high prediction score of 0.994 (99.41%), reflecting strong topological association between the BDP node and the atopic eczema node. This computational signal is reinforced by a double-blind, placebo-controlled RCT (Heddle et al., 1984) in which combined oral plus nasal BDP produced statistically significant improvement in 26 children with severe atopic eczema over 4 weeks. However, this trial is over 40 years old, and no contemporary registered trials have been identified — making this a promising but unvalidated hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6434024	1984	RCT	British Medical Journal	Double-blind, placebo-controlled crossover trial in 26 children with severe atopic eczema: combined oral + nasal BDP significantly improved symptoms vs. placebo over 4 weeks; mild HPA suppression noted
1476023	1992	Clinical Trial	Acta Derm Venereol Suppl	Oral BDP achieved stable disease control in 10/14 children with severe atopic dermatitis (mean dose 1,000 µg/day); linear growth deceleration observed at maintenance doses
30911861	2019	Formulation Study	AAPS PharmSciTech	BDP mixed micelles incorporated into biocompatible hydrogel for dermal delivery; validated in sub-chronic dermatitis animal model — supports novel delivery strategies
14522624	2003	Clinical Observational	J Dermatol Treat	Wet-wrap steroid therapy in prepubertal children with atopic eczema monitored for short-term growth and bone turnover; systemic corticosteroid effects quantified
19571596	2009	Review	Neuroimmunomodulation	Intranasal corticosteroids (including BDP) and HPA axis suppression: summarises systemic exposure risk and monitoring methods — directly relevant for safety assessment
11488426	2001	Review	Jpn J Pharmacol	BDP and fluticasone confirmed as core inhaled glucocorticoids for allergic disease; contextualises BDP’s class-level evidence for Th2-driven conditions
8765824	1996	Experimental	J Allergy Clin Immunol	Topical steroids enhance in vitro spontaneous IgE production in atopic dermatitis patients — important safety signal regarding glucocorticoid use in this indication
19874229	2009	Experimental	Immunopharmacol Immunotoxicol	Mouse model comparison of BDP vs. mometasone furoate: MF showed greater local anti-inflammatory potency with lower systemic effects than BDP — reference benchmark for drug positioning
14616123	2003	Review	Allergy	Corticosteroid allergy in asthma patients: delayed contact allergy and occasional immediate hypersensitivity documented — safety consideration for topical or systemic BDP use
37023229	2023	Computational	J Chem Inf Model	DrugRep-KG framework validates knowledge graph approaches to drug repurposing; supports the computational basis of the TxGNN BDP–atopic eczema prediction

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Th2-suppressive mechanism of BDP aligns directly with atopic eczema pathology, and an early RCT provides proof-of-concept for oral/nasal BDP in severe paediatric disease. However, this evidence is over 40 years old, no current registered trials exist, key regulatory safety data are unavailable, and the drug holds no approved license in this market — the evidence base is insufficient to justify advancement to a formal repurposing program at this stage.

To proceed, the following is needed:

Retrieve the full package insert (FDA/TFDA) to resolve blocking data gaps on warnings, contraindications, and paediatric safety profile
Query DrugBank API to confirm and document the formal mechanism of action (resolves DG002)
Conduct an updated systematic literature search for post-2000 clinical studies evaluating oral, intranasal, or systemic BDP specifically in atopic eczema
Expand ClinicalTrials.gov search using broader terms (e.g., “beclomethasone dermatitis”, “glucocorticoid atopic eczema”) to verify absence of ongoing trials
Evaluate route compatibility in detail: determine whether oral, nasal, or a novel formulation route (e.g., hydrogel micelles per PMID 30911861) is the intended repurposing pathway
Assess HPA axis suppression and growth safety data before any paediatric use planning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.